Finn RS - Search Results

1

Management of ER positive metastatic breast cancer.

McAndrew NP, Finn RS. McAndrew NP, et al. Among authors: finn rs. Semin Oncol. 2020 Oct;47(5):270-277. doi: 10.1053/j.seminoncol.2020.07.005. Epub 2020 Aug 29. Semin Oncol. 2020. PMID: 32958261 Review.

2

Monoclonal antibody therapy for breast cancer: herceptin.

Finn RS, Slamon DJ. Finn RS, et al. Cancer Chemother Biol Response Modif. 2003;21:223-33. doi: 10.1016/s0921-4410(03)21010-3. Cancer Chemother Biol Response Modif. 2003. PMID: 15338747 Review. No abstract available.

3

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Konecny GE, et al. Cancer Res. 2006 Feb 1;66(3):1630-9. doi: 10.1158/0008-5472.CAN-05-1182. Cancer Res. 2006. PMID: 16452222

4

Targeting Src in breast cancer.

Finn RS. Finn RS. Ann Oncol. 2008 Aug;19(8):1379-1386. doi: 10.1093/annonc/mdn291. Epub 2008 May 16. Ann Oncol. 2008. PMID: 18487549 Free article. Review.

5

A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.

Britten CD, Finn RS, Bosserman LD, Wong SG, Press MF, Malik M, Lum BL, Slamon DJ. Britten CD, et al. Among authors: finn rs. Clin Breast Cancer. 2009 Feb;9(1):16-22. doi: 10.3816/CBC.2009.n.003. Clin Breast Cancer. 2009. PMID: 19299235 Free PMC article. Clinical Trial.

6

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.

Finn RS, Press MF, Dering J, Arbushites M, Koehler M, Oliva C, Williams LS, Di Leo A. Finn RS, et al. J Clin Oncol. 2009 Aug 20;27(24):3908-15. doi: 10.1200/JCO.2008.18.1925. Epub 2009 Jul 20. J Clin Oncol. 2009. PMID: 19620495 Free PMC article. Clinical Trial.

7

What's positive about 'triple-negative' breast cancer?

Hurvitz SA, Finn RS. Hurvitz SA, et al. Among authors: finn rs. Future Oncol. 2009 Sep;5(7):1015-25. doi: 10.2217/fon.09.68. Future Oncol. 2009. PMID: 19792970 Review.

8

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.

Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M, Koehler M. Finn RS, et al. J Clin Oncol. 2009 Nov 20;27(33):5552-8. doi: 10.1200/JCO.2008.21.1763. Epub 2009 Oct 26. J Clin Oncol. 2009. PMID: 19858400 Clinical Trial.

9

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. Finn RS, et al. Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419. Breast Cancer Res. 2009. PMID: 19874578 Free PMC article.

10

Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.

Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ. Finn RS, et al. Clin Cancer Res. 2011 Nov 1;17(21):6905-13. doi: 10.1158/1078-0432.CCR-11-0288. Epub 2011 Oct 25. Clin Cancer Res. 2011. PMID: 22028489

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256 results

Search Page

Filters